Zentalis Pharmaceuticals Sees Unusually High Options Volume (NASDAQ:ZNTL)

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) was the target of unusually large options trading on Wednesday. Stock traders purchased 2,113 call options on the company. This is an increase of approximately 571% compared to the typical daily volume of 315 call options.

Institutional Investors Weigh In On Zentalis Pharmaceuticals

Several institutional investors have recently modified their holdings of ZNTL. Erste Asset Management GmbH purchased a new position in shares of Zentalis Pharmaceuticals in the 3rd quarter valued at $37,000. Paloma Partners Management Co purchased a new position in shares of Zentalis Pharmaceuticals in the 3rd quarter valued at about $37,000. Aigen Investment Management LP acquired a new stake in Zentalis Pharmaceuticals in the third quarter valued at $41,000. Capstone Investment Advisors LLC acquired a new position in shares of Zentalis Pharmaceuticals during the 3rd quarter worth $48,000. Finally, China Universal Asset Management Co. Ltd. boosted its position in shares of Zentalis Pharmaceuticals by 63.9% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 13,676 shares of the company’s stock worth $50,000 after buying an additional 5,333 shares in the last quarter.

Analyst Upgrades and Downgrades

ZNTL has been the topic of a number of recent research reports. HC Wainwright restated a “buy” rating and set a $20.00 price objective on shares of Zentalis Pharmaceuticals in a research report on Friday, November 15th. Wedbush reiterated a “neutral” rating and set a $4.00 price target on shares of Zentalis Pharmaceuticals in a report on Friday, January 24th. Guggenheim cut their target price on Zentalis Pharmaceuticals from $12.00 to $8.00 and set a “buy” rating on the stock in a research note on Friday, November 15th. Finally, UBS Group decreased their price target on Zentalis Pharmaceuticals from $5.00 to $2.20 and set a “neutral” rating for the company in a research note on Tuesday. Five research analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $9.69.

Zentalis Pharmaceuticals Stock Performance

Shares of ZNTL stock traded down $0.32 during trading hours on Wednesday, reaching $2.08. The company had a trading volume of 7,106,960 shares, compared to its average volume of 2,534,725. Zentalis Pharmaceuticals has a 12-month low of $1.77 and a 12-month high of $18.07. The company has a market capitalization of $148.51 million, a price-to-earnings ratio of -0.85 and a beta of 1.86. The stock has a fifty day moving average of $3.02 and a 200-day moving average of $3.31.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.56) EPS for the quarter, topping the consensus estimate of ($0.92) by $0.36. On average, analysts forecast that Zentalis Pharmaceuticals will post -2.48 EPS for the current year.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.